1. Home
  2. RCEL vs AVR Comparison

RCEL vs AVR Comparison

Compare RCEL & AVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCEL
  • AVR
  • Stock Information
  • Founded
  • RCEL N/A
  • AVR 1999
  • Country
  • RCEL United States
  • AVR Australia
  • Employees
  • RCEL N/A
  • AVR N/A
  • Industry
  • RCEL Medical/Dental Instruments
  • AVR
  • Sector
  • RCEL Health Care
  • AVR
  • Exchange
  • RCEL Nasdaq
  • AVR NYSE
  • Market Cap
  • RCEL 161.5M
  • AVR 162.1M
  • IPO Year
  • RCEL N/A
  • AVR 2024
  • Fundamental
  • Price
  • RCEL $5.15
  • AVR $3.48
  • Analyst Decision
  • RCEL Strong Buy
  • AVR Strong Buy
  • Analyst Count
  • RCEL 4
  • AVR 4
  • Target Price
  • RCEL $16.50
  • AVR $16.50
  • AVG Volume (30 Days)
  • RCEL 316.4K
  • AVR 309.1K
  • Earning Date
  • RCEL 08-07-2025
  • AVR 08-16-2025
  • Dividend Yield
  • RCEL N/A
  • AVR N/A
  • EPS Growth
  • RCEL N/A
  • AVR N/A
  • EPS
  • RCEL N/A
  • AVR N/A
  • Revenue
  • RCEL $71,661,000.00
  • AVR $2,493,000.00
  • Revenue This Year
  • RCEL $57.16
  • AVR $25.79
  • Revenue Next Year
  • RCEL $36.69
  • AVR $211.91
  • P/E Ratio
  • RCEL N/A
  • AVR N/A
  • Revenue Growth
  • RCEL 41.35
  • AVR N/A
  • 52 Week Low
  • RCEL $4.71
  • AVR $2.34
  • 52 Week High
  • RCEL $14.16
  • AVR $8.79
  • Technical
  • Relative Strength Index (RSI)
  • RCEL 41.07
  • AVR N/A
  • Support Level
  • RCEL $5.11
  • AVR N/A
  • Resistance Level
  • RCEL $5.53
  • AVR N/A
  • Average True Range (ATR)
  • RCEL 0.29
  • AVR 0.00
  • MACD
  • RCEL 0.10
  • AVR 0.00
  • Stochastic Oscillator
  • RCEL 62.22
  • AVR 0.00

About RCEL Avita Medical Inc.

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

About AVR ANTERIS TECHNOLOGIES GLOBAL CORP

Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.

Share on Social Networks: